Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Publication date: 2024

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Publication Year: 2024

Authors & Co-authors:  Hoffman Risa M RM Brummel Sean S Ziemba Lauren L Chinula Lameck L McCarthy Katie K Fairlie Lee L Jean-Philippe Patrick P Chakhtoura Nahida N Johnston Ben B Krotje Chelsea C

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.

Journal: Lancet (London, England)

Publication date: 2021

Journal: Lancet (London, England)

Publication Year: 2021

Authors & Co-authors:  Lockman Brummel Ziemba Stranix-Chibanda McCarthy Coletti Jean-Philippe Johnston Krotje Fairlie

Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis.

Journal: PloS one

Publication date: 2022

Journal: PloS one

Publication Year: 2022

Authors & Co-authors:  Singh Lant Cividini Cattrall Goodwin Benjamin Michael Khawaja Matos Alkeridy